Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid ...

Ensartinib offers improved progression-free survival for ALK-positive NSCLC compared with crizotinib, with a median PFS of 25.8 months vs 12.7 months. Adverse events with ensartinib are mostly mild, ...

New targeted drugs transform HER2, ROS1 and ALK lung cancer care, boosting brain response and survival—while precision choices still matter.

Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung a | Six years after the FDA approved Eli Lilly’s ...

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...

Alecensa achieved a 4-year OS rate of 98.4% in resected ALK-positive early-stage NSCLC, outperforming chemotherapy. The ALINA study showed a 65% reduction in disease recurrence or death risk with ...

Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small ...

ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non–Small Cell Lung ...

The months ahead will determine whether they will become turning points or missed opportunities. Cancer does not wait for GDP targets, and patients cannot wait for promises to turn into action ...